Over 3000 patients have responded to an online request from Boston researchers to contribute tumor tissue and saliva for the purpose of accelerating research on metastatic breast cancer.

Dr Maurie Markman explains that sharing genetic data with study participants encourages greater clinical trial involvement.

Dr Harold Burstein reviews the latest data on duration of adjuvant endocrine therapy in metastatic breast cancer, and provides much-needed recommendations on how to approach the topic with patients.

Drs Ann LaCasce and Kerry Savage discuss the most interesting lymphoma studies presented at ASH 2016, including the CALGB/Alliance 50303, GOYA, and GALLIUM trials.

The presentations at ASH 2016 for multiple myeloma focused on novel drug combinations in various settings, including newly diagnosed myeloma and refractory disease.

One of the greatest worries of a cancer patient is the possibility of a painful death. Unfortunately, a painless death is not something that many oncologists around the world are able to promise.

Dr Weber discusses two studies that show a clear survival advantage with ipilimumab, but at a significant price in toxicity.

Patients with advanced HR-positive/HER2-negative breast cancer may benefit from practice-changing treatment options, as reported by Dr Javier Cortés from ESMO 2016.

Dr Caroline Robert reviews melanoma highlights from ESMO 2016, focusing on results of ipilimumab in the adjuvant setting and the highest 3-year survival achieved in metastatic disease.

How do adverse events from immunotherapy compare in younger vs older patients? Dr Weber comments on the safety of checkpoint inhibitors for our older patients.